Overview

Combination Treatment With Cerebrolysin and Amantadine on Patients Who Stays in Prolonged Disorders of Consciousness Due to Severe Traumatic Brain Injury

Status:
Not yet recruiting

Trial end date:
2021-09-01

Target enrollment:

Participant gender:

Summary

Object: To demonstrate the combined effect of cerebrolysin and amantadine on prolonged disorders of consciousness in patients with severe traumatic brain injury Participants: patients with prolonged disorders of consciousness due to severe traumatic brain injury Intervention: amantadine only (100mg to 200mg bid) or cerebrolysin only (30ml qd) or amantadine (100mg to 200mg bid) plus cerebrolysin (30ml qd) Comparison: amantadine only group versus cerebrolysin only group versus amantadine plus cerebrolysin group Outcome: Coma Recovery Scale-revised, FDG-PET signal

Phase:

Phase 4

Details

Lead Sponsor:

Konkuk University Medical Center

Collaborator:

Ever Neuro Pharma GmbH

Treatments:

Amantadine
Cerebrolysin